Published in J Clin Invest on October 01, 1984
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest (1986) 1.40
The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol (1989) 1.24
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions. Clin Exp Immunol (1988) 1.06
Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 1.05
Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest (1985) 1.04
Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans. Clin Exp Immunol (1987) 1.02
A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol (2005) 0.99
In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest (1989) 0.97
Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia. Mol Med (2008) 0.93
Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes. Clin Exp Immunol (1992) 0.92
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
The rate of loss of CR1 from ageing erythrocytes in vivo in normal subjects and SLE patients: no correlation with structural or numerical polymorphisms. Clin Exp Immunol (1988) 0.92
Immune complex processing in C1q-deficient mice. Clin Exp Immunol (2001) 0.90
A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology (2003) 0.90
Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin Exp Immunol (1992) 0.81
Elimination of soluble 123I-labelled aggregates of human immunoglobulin G in humans; the effect of splenectomy. Clin Exp Immunol (1989) 0.81
Immune adherence and clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1991) 0.81
A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1). Clin Exp Immunol (1987) 0.80
Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans. Clin Exp Immunol (1989) 0.79
Deficiency of complement component C3 is associated with accelerated removal of soluble 123I-labelled aggregates of IgG from the circulation. Clin Exp Immunol (1992) 0.79
Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes. Immunology (1993) 0.78
Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1. J Biol Chem (2014) 0.75
Targeted FcγR mediated clearance by a biparatopic bispecific antibody. J Biol Chem (2017) 0.75
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci U S A (1975) 3.97
Studies on the mechanism of solubilization of immune precipitates by serum. J Exp Med (1976) 3.68
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med (1982) 3.40
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 2.68
Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clin Exp Immunol (1982) 2.20
A simple numerical method for the construction of isokinetic sucrose density gradients, and their application to the characterisation of immunoglobulin complexes. J Immunol Methods (1976) 1.95
Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med (1977) 1.79
Studies on antigen-antibody complexes. II. Quantification of tissue uptake of soluble complexes in normal and complement-depleted rabbits. J Immunol (1971) 1.77
Competition for immune complexes by red cells in human blood. J Clin Lab Immunol (1982) 1.74
Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med (1971) 1.74
The disappearance kinetics and glomerular deposition of small-latticed soluble immune complexes. Immunology (1982) 1.54
Complement-dependent alterations in the handling of immune complexes by NZB/W mice. J Immunol (1975) 1.28
Inherited complement deficiency states and SLE. Clin Rheum Dis (1982) 1.25
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
Clearance and tissue uptake of immune complexes in complement-depleted and control mice. Immunology (1981) 1.20
Decreased complement mediated binding of antibody/3H-dsDNA immune complexes to the red blood cells of patients with systemic lupus erythematosus, rheumatoid arthritis, and hematologic malignancies. Arthritis Rheum (1983) 1.19
Clearance kinetics of soluble pre-formed immune complexes containing IgM antibodies in normal and decomplemented rabbits. Immunology (1981) 1.17
Classical complement pathway activation in membranoproliferative glomerulonephritis. Kidney Int (1976) 1.15
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor. Clin Exp Immunol (1982) 1.03
The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study. Am J Med (1978) 1.01
Genetic deficiency of the second component of complement (C2) associated with systemic lupus erythematosus. Relation of the complement abnormality and disease manifestations. Am J Med (1977) 0.98
A postulated mechanism for heparin's potentiation of C1 inhibitor function. Mol Immunol (1982) 0.97
Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor. Clin Immunol Immunopathol (1984) 0.90
Complement-mediated delay in immune complex clearance from the blood owing to reduced deposition outside the reticuloendothelial system. Immunology (1983) 0.90
Heterogeneity of the clinical syndrome in patients with systemic lupus erythematosus and genetic deficiency of the second complement component. Clin Exp Immunol (1978) 0.86
Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. J Lab Clin Med (1981) 0.86
Circulating immune complexes and glomerulonephritis in a patient with congenital absence of the third component of complement. N Engl J Med (1983) 0.86
The effect of continuous normalization of serum hemolytic complement on the course of lupus nephritis: a five year prospective study. Am J Med (1981) 0.84
The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis. Clin Nephrol (1979) 0.84
In vivo generation and clearance of soluble immune complexes containing IgM antibodies in normal and decomplemented rabbits. Clin Exp Immunol (1981) 0.83
Inhibition of the enzymatic activity of the first component of complement (C1) by heparin. Clin Immunol Immunopathol (1976) 0.80
Complement and glomerular disease - a natural history study. Nephron (1981) 0.78
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker. Kidney Int (2007) 2.84
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82
The living donor in kidney transplantation. Ann Intern Med (1987) 1.81
Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest (1966) 1.81
Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA (1976) 1.77
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1991) 1.66
Therapy of membranous nephropathy: what to do after the after (meta) analyses. J Am Soc Nephrol (1995) 1.39
Renoprotective therapy: how good can it get? Kidney Int (2000) 1.39
CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev (2001) 1.27
Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood (2001) 1.25
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol (2005) 1.25
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int (2007) 1.18
Renal artery dissection causing renal infarction in otherwise healthy men. Am J Kidney Dis (1997) 1.17
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol (2012) 1.10
Pseudomonas septicemia in neutropenic dogs. I. Treatment with granulocyte transfusions. Transfusion (1974) 1.10
The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int (1987) 1.07
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol (1987) 1.04
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Complement activation induces the expression of decay-accelerating factor on human mesangial cells. J Immunol (1991) 1.02
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis (1999) 1.02
Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. Am J Pathol (1994) 1.01
The effect of sodium hydroxide and hydrochloric acid on human epidermis. An electronmicroscopic study. Acta Derm Venereol (1972) 1.01
Regulation of paralytic experimental allergic encephalomyelitis in rats: susceptibility to active and passive disease reinduction. J Immunol (1981) 1.00
Identification of the Kna/Knb polymorphism and a method for Knops genotyping. Transfusion (2004) 0.99
Diagnostic significance of hypocomplementemia. Kidney Int (1991) 0.97
Interactions between precipitating and nonprecipitating antibodies in the formation of immune complexes. J Immunol (1987) 0.97
Measurement of the fractional uptake of macromolecules by the renal vascular bed compared to other vascular beds. J Lab Clin Med (1976) 0.97
Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol (1990) 0.95
The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Am J Med Sci (1995) 0.93
Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol (1999) 0.93
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus (2011) 0.92
Subacute bacterial endocarditis masquerading as type III essential mixed cryoglobulinemia. J Am Soc Nephrol (1997) 0.91
Resection of the internal carotid artery and replacement with greater saphenous vein: a safe procedure for en bloc cancer resections with carotid involvement. J Vasc Surg (1996) 0.91
NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology (Williston Park) (2000) 0.91
Modification of the clinical and histopathologic expression of experimental allergic encephalomyelitis by the vasoactive amine antagonist cyproheptadine. Cell Immunol (1984) 0.90
Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int (1991) 0.90
Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor. Clin Immunol Immunopathol (1984) 0.90
Saphenous vein stripping and its complications. Surg Clin North Am (1983) 0.89
Progressive myelopathy in older German shepherd dogs. II. Presence of circulating suppressor cells. J Immunol (1980) 0.89
Randomized trial of emergency mesocaval and portacaval shunts for bleeding esophageal varices. Am J Surg (1978) 0.89
The effect of oxidant injury on the lymphocyte membrane and functions. J Lab Clin Med (1981) 0.88
Progressive myelopathy in older German shepherd dogs. I. Depressed response to thymus-dependent mitogens. J Immunol (1980) 0.88
Arteriovenous fistulae complicating cardiac pacemaker lead extraction: recognition, evaluation, and management. J Vasc Surg (2000) 0.88
The role of echocardiography in patients with acute peripheral arterial embolization. Ann Vasc Surg (1986) 0.88
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res (1999) 0.88
Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol (1985) 0.87
Use of the splenic and hepatic artery for renal revascularization in patients with atherosclerotic renal artery disease. Ann Vasc Surg (1997) 0.86
Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes. Cell Immunol (1992) 0.86
Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res (1987) 0.86
Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood (1986) 0.85
Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus (2012) 0.85
Immune complexes bind preferentially to specific subpopulations of human erythrocytes. Clin Immunol Immunopathol (1990) 0.85
Glomerular deposition of immune complexes made with IgG2a monoclonal antibodies. J Immunol (2000) 0.84
Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates. J Lab Clin Med (1990) 0.84
Hepatorenal and splenorenal artery bypass for salvage of renal function. Ann Vasc Surg (1991) 0.84
Of mice and men: the relevance of the mouse to the study of human SLE. Immunol Res (2001) 0.83
Reversal of chronic end-stage renal failure due to myeloma kidney. Ann Intern Med (1979) 0.83
Activation of the alternative complement pathway in ascitic fluid during spontaneous bacterial peritonitis. J Clin Gastroenterol (1982) 0.82
Rapidly progressive glomerulonephritis superimposed on diabetic glomerulosclerosis. Recognition and treatment. JAMA (1982) 0.82
Glucose: a role as a free radical scavenger in biological systems. J Lab Clin Med (1983) 0.82
The chimpanzee and cynomolgus monkey erythrocyte immune adherence receptors are encoded by CR1-like genes. Immunogenetics (2000) 0.82
Lentigo maligna of the fingertip. Clinical, histologic, and ultrastructural studies of two cases. Arch Dermatol (1973) 0.82
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res (2007) 0.82
Renal subcapsular pressure--a new intrarenal pressure measurement. Am J Physiol (1971) 0.82
Radial artery cannulation: a comparison of 15.2- and 4.45-cm catheters. J Clin Monit (1992) 0.82
Ig N-glycan orientation can influence interactions with the complement system. J Immunol (1997) 0.81
The presence of specific antigen-reactive cells during the induction, recovery, and resistance phases of experimental allergic encephalomyelitis. Cell Immunol (1980) 0.81
Experimental immune complex-mediated glomerulonephritis in the nonhuman primate. Kidney Int (1991) 0.81
The role of the complement system in renal injury. Semin Nephrol (1992) 0.81
Biologic significance of the erythrocyte complement receptor: a primate perquisite. J Lab Clin Med (1991) 0.81
Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35). J Am Soc Nephrol (1994) 0.80